177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry — Stella

Home/Neuroendocrine Tumors/

View on ClinicalTrials.gov

Recruiting

Back to Neuroendocrine Tumors trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa

Key details

Phase

Safety & dosing

Sponsor

University of Iowa

Collaborators

Novartis

Enrollment target

~120 participants

Started

May 2024

Primary completion

December 2029

Age range

18 Years and older

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.